Mesenchymal Stem Cells Market Research Report Information By Products & Services (Workflow, Product and Services), By Type (Autologous and Allogenic), By Source of Isolation (Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung and Adipose Tissues), By Indication (Bone and Cartilage Repair, Cardiovascular Disease, Inflammatory & Immunological Diseases, Liver Diseases, Cancer, GvHD and Others), By Application (Disease Modeling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and

Global Mesenchymal Stem Cells Market Overview

Mesenchymal Stem Cells Market Size was valued at USD 2.7 Billion in 2022. The Mesenchymal Stem Cells market industry is projected to grow from USD 3.1 Billion in 2023 to USD 8.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.00% during the forecast period (2024 - 2032). Increased incidence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune diseases is one of the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Mesenchymal Stem Cells Market Trends

• Growing prevalence of chronic diseases is driving the market growth

Market CAGR for mesenchymal stem cells is being driven by the growing prevalence of chronic diseases. MSC-based therapies offer promising avenues for treatment due to their regenerative and immunomodulatory properties. As conventional treatment options often fall short of providing comprehensive solutions, the demand for innovative therapies is rising. MSCs, with their potential to repair damaged tissues and modulate immune responses, present a compelling solution. Consequently, pharmaceutical companies, biotechnology firms, and research institutions are increasingly investing in the development and commercialization of MSC-based products. This trend is expected to persist as the burden of chronic diseases continues to grow, emphasizing the crucial role MSCs play in addressing unmet medical needs.

The increasing awareness and acceptance of Mesenchymal Stem Cell (MSC) therapies among healthcare professionals and patients are key drivers of the MSC market. As knowledge about the regenerative and immunomodulatory properties of MSCs spreads, healthcare providers are more inclined to explore and recommend these innovative treatments. Moreover, patients are actively seeking alternative therapies, particularly for conditions with limited treatment options or unsatisfactory outcomes with conventional approaches. This growing acceptance fosters a supportive environment for the development and commercialization of MSC-based products. Additionally, advocacy groups, patient testimonials, and media coverage contribute to raising awareness and driving demand. As a result, pharmaceutical companies and biotechnology firms are investing more resources into MSC research and development, leading to the expansion of the MSC market and the emergence of novel therapeutic applications.

Advancements in stem cell research play a pivotal role in propelling the Mesenchymal Stem Cells (MSCs) market forward. Continuous innovation in isolation techniques, expansion protocols, and characterization methods enhances our understanding of MSCs' therapeutic potential and widens their applicability across various medical fields. These advancements facilitate the development of more efficient and scalable manufacturing processes, ensuring the availability of high-quality MSC-based products for clinical use. Moreover, breakthroughs in gene editing technologies and biomaterials enable the customization and enhancement of MSCs' properties, further expanding their therapeutic capabilities. As stem cell research progresses, novel insights into MSC biology and functionality drive the discovery of new therapeutic targets and treatment modalities, fostering collaboration between academia and industry to translate scientific discoveries into clinically relevant therapies, ultimately driving the growth of the MSC market revenue.

For instance, Aspen Neuroscience, Inc., initiated the inaugural patient screening study, collaborating with multiple clinical screening sites across the United States. The company's Trial-Ready Cohort Study serves as an initial phase preceding the submission of an Investigational New Drug (IND) application to the United States Food & Drug Administration. Their focus lies on ANPD001 and the exploration of iPSC-derived cell replacement therapies designed for Parkinson's disease treatment.

Mesenchymal Stem Cells Market Segment Insights

• Mesenchymal Stem Cells Products & Services Insights

The Mesenchymal Stem Cells Market segmentation, based on products & services, includes Workflow, Product and Services. In 2023, the Workflow segment dominated the market, accounting for 30% of market revenue due to their crucial role in streamlining and optimizing the entire process chain, from isolation and expansion to characterization and application of MSCs. These products and services encompass a wide range of offerings, including cell culture media, reagents, instruments, and protocols, which are essential for the efficient production and utilization of MSC-based therapies. Their integral contribution to workflow efficiency and product quality makes them highly sought-after in the MSC market.

Product products and services are experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to increasing demand for innovative and advanced MSC-based therapeutic products. This growth is driven by ongoing research and development efforts focused on developing novel MSC-based therapies for various medical conditions. Additionally, advancements in manufacturing technologies and improved scalability of MSC production contribute to the expansion of product offerings, leading to higher growth rates in this segment of the market.

Mesenchymal Stem Cells Type Insights

The Mesenchymal Stem Cells Market segmentation, based on type, includes Autologous and Allogenic. In 2023, the autologous category generated the most income due to its compatibility and reduced risk of rejection. Autologous MSCs are derived from the patient's tissues, minimizing the likelihood of immune rejection or adverse reactions. This type of MSC therapy offers personalized treatment options tailored to individual patients, thereby gaining preference among healthcare providers and patients alike. Additionally, autologous MSCs eliminate the need for immunosuppressive drugs, enhancing their appeal and driving market dominance.

The Allogenic type is experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to several factors. Allogenic MSC therapies offer off-the-shelf solutions, providing easier access to treatment for a broader patient population compared to autologous therapies. Additionally, advancements in tissue matching and immunomodulatory techniques have reduced the risk of rejection, making allogenic MSCs a viable option for many patients. The scalability and cost-effectiveness of allogenic therapies further contribute to their rapid growth in the market.

Figure 1: Mesenchymal Stem Cells Market, by Type, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Mesenchymal Stem Cells Source of Isolation Insights

The Mesenchymal Stem Cells Market segmentation, based on the source of isolation, includes Bone marrow, Cord blood, Peripheral blood, Fallopian tube, Fetal liver, Lung, and Adipose tissues. In 2023, the bone marrow category generated the most income due to several factors. It has long been recognized as a rich source of MSCs, providing a relatively high yield of cells with potent regenerative properties. Moreover, bone marrow-derived MSCs have demonstrated efficacy in various preclinical and clinical studies across a wide range of therapeutic applications, contributing to their widespread adoption and dominance in the market.

Cord blood as a source of isolation is experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to several reasons. Cord blood-derived MSCs offer unique advantages, including non-invasive collection methods and a higher proliferative capacity compared to other tissue sources. Additionally, growing research interest and clinical trials exploring the therapeutic potential of cord blood-derived MSCs in various medical conditions are driving their increased adoption, contributing to their rapid growth in the market.

Mesenchymal Stem Cells Indication Insights

The Mesenchymal Stem Cells Market segmentation, based on indication, includes Bone and cartilage repair, Cardiovascular disease, Inflammatory & immunological diseases, Liver diseases, Cancer, GvHD, and Others. In 2023, the bone and cartilage repair category generated the most income due to several key factors. MSC-based therapies have demonstrated significant potential for promoting tissue regeneration and modulating inflammatory responses, making them particularly effective for addressing conditions such as osteoarthritis, bone fractures, and cartilage injuries. Additionally, the increasing prevalence of musculoskeletal disorders and the limited efficacy of conventional treatments have fueled demand for innovative MSC-based therapies, driving their dominance in this indication.

Cardiovascular disease (CVD) indications are experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to several factors. MSC-based therapies show promising results in preclinical and clinical studies for treating various cardiovascular conditions, including myocardial infarction, heart failure, and peripheral artery disease. With the increasing prevalence of CVD globally and the limited effectiveness of current treatments, there is growing interest in exploring MSC-based therapies as potential regenerative solutions, driving their rapid growth in this indication.

Mesenchymal Stem Cells Application Insights

The Mesenchymal Stem Cells Market segmentation, based on application, includes Disease modeling, Drug development & discovery, Stem cell banking, Tissue engineering, Toxicology studies, and Others. In 2023, the disease modeling category generated the most income due to its pivotal role in advancing personalized medicine and drug discovery. MSCs serve as valuable tools for modeling various diseases in vitro, providing researchers with a platform to study disease mechanisms, screen potential therapeutics, and develop patient-specific treatment approaches. With the increasing focus on precision medicine and the demand for more effective therapies, the disease modeling application of MSCs has become increasingly essential, driving its dominance in the market.

The Drug development & discovery application is experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to several factors. MSCs offer a versatile platform for drug screening, toxicity testing, and disease modeling, aiding in the development of safer and more effective therapeutics. Moreover, advancements in cell culture techniques, high-throughput screening methods, and bioinformatics tools have enhanced the utility and scalability of MSC-based assays, driving their increased adoption in drug discovery and development processes.

Mesenchymal Stem Cells Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Mesenchymal Stem Cells market area will dominate this market with advanced research facilities. North America has secured the largest market share in the Mesenchymal Stem Cells (MSCs) market due to several key factors. The region benefits from a well-established healthcare infrastructure, advanced research facilities, and supportive regulatory frameworks that facilitate the development and commercialization of MSC-based therapies. Additionally, strong investment in stem cell research, a high prevalence of chronic diseases, and a favorable reimbursement landscape contribute to the widespread adoption of MSC-based treatments, driving market dominance in North America.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: MESENCHYMAL STEM CELLS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Mesenchymal Stem Cells market accounts for the second-largest market share due to the renowned research institutions. Europe has captured the second largest market share in the Mesenchymal Stem Cells (MSCs) market owing to various factors. The region boasts advanced healthcare systems, renowned research institutions, and a robust regulatory environment conducive to stem cell research and development. Moreover, increasing investments in regenerative medicine, growing awareness about the therapeutic potential of MSC-based therapies, and collaborations between academia and industry have fueled the adoption of MSC products and treatments, contributing to Europe's significant market presence in this sector. Further, the German Mesenchymal Stem Cells market held the largest market share, and the UK Mesenchymal Stem Cells market was the fastest growing market in the European region.

The Asia-Pacific Mesenchymal Stem Cells Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest compound annual growth rate (CAGR) in the Mesenchymal Stem Cells (MSCs) market due to several factors. These include a rapidly expanding healthcare infrastructure, increasing investments in biotechnology and regenerative medicine, and a large patient population with unmet medical needs. Additionally, supportive government initiatives, rising healthcare expenditure, and growing awareness about the benefits of MSC-based therapies are driving market growth in the region, making it a key contributor to the overall market expansion. Moreover, China’s Mesenchymal Stem Cells market held the largest market share, and the Indian Mesenchymal Stem Cells market was the fastest growing market in the Asia-Pacific region.

Mesenchymal Stem Cells Key Market Players & Competitive Insights

Leading players in the competitive landscape of the Mesenchymal Stem Cells market are focusing on strategic initiatives such as mergers and acquisitions, collaborations, and product launches to strengthen their market position. They are investing in research and market developments to expand their product portfolios and explore new therapeutic applications for MSC-based therapies. Additionally, companies are leveraging advancements in manufacturing technologies and expanding their global presence through partnerships and distribution agreements to capitalize on emerging opportunities in the MSCs market.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Mesenchymal Stem Cells industry to benefit clients and increase the market sector. In recent years, the Mesenchymal Stem Cells industry has offered some of the most significant advantages to autologous. Major players in the Mesenchymal Stem Cells market, including Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, StemCells Inc., Mesoblast Ltd., Cellular Dynamics International, PromoCell GmbH, Celgene Corporation, Osiris Therapeutics, Inc., Pluristem Therapeutics Inc. and others, are attempting to increase market demand by investing in research and development operations.

Lonza Group is a key player in the Mesenchymal Stem Cells (MSCs) market, offering a comprehensive portfolio of products and services for cell therapy applications. The company provides advanced manufacturing solutions for MSC-based therapies, including cell culture media, reagents, and process development services. Lonza's expertise in bioprocessing and cell therapy manufacturing enables efficient scale-up and commercialization of MSC products. Additionally, Lonza has strategic collaborations and partnerships with academic institutions, biopharmaceutical companies, and research organizations to accelerate innovation and advance MSC-based therapies for various medical indications. With a global presence and a focus on quality, compliance, and innovation, Lonza Group plays a significant role in shaping the future of the MSCs market.

Mesoblast Ltd. is a leading biopharmaceutical company specializing in the development and commercialization of novel cellular therapies, including Mesenchymal Stem Cells (MSCs). The company's proprietary platform technology enables the scalable production of MSCs with potent immunomodulatory and regenerative properties. Mesoblast is focused on advancing MSC-based therapies for a range of medical conditions, including cardiovascular diseases, orthopedic disorders, and inflammatory conditions. With a robust pipeline of clinical-stage candidates and strategic partnerships with pharmaceutical companies, Mesoblast aims to address significant unmet medical needs and bring transformative therapies to patients worldwide. The company's commitment to innovation, scientific excellence, and clinical development positions it as a key player in the evolving landscape of MSC-based treatments.

Key Companies in the Mesenchymal Stem Cells market include

• Lonza Group


• Thermo Fisher Scientific Inc.


• Merck KGaA


• StemCells Inc.


• Mesoblast Ltd.


• Cellular Dynamics International


• PromoCell GmbH


• Celgene Corporation


• Osiris Therapeutics, Inc.


• Pluristem Therapeutics Inc.

Mesenchymal Stem Cells Industry Developments

February 2022: The US FDA approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) to treat adults with relapsed or refractory multiple myeloma (RRMM) following four or more prior lines of therapy. CARVYKTI is an autologous T-cell immunotherapy that has been genetically modified to target B-cell maturation antigen.

January 2023: Glenmark Pharmaceuticals, a renowned global pharmaceutical company, introduced sacubitril + valsartan tablets in India as a prescription-only medication for treating heart failure. These tablets, marketed under the brand name 'Sacu V,' provide a promising therapeutic option for patients suffering from heart failure.

Mesenchymal Stem Cells Market Segmentation

Mesenchymal Stem Cells Products & Services Outlook

• Workflow


• Product


• Services

Mesenchymal Stem Cells Type Outlook

• Autologous


• Allogenic

Mesenchymal Stem Cells Source of Isolation Outlook

• Bone marrow


• Cord blood


• Peripheral blood


• Fallopian tube


• Fetal liver


• Lung


• Adipose tissues

Mesenchymal Stem Cells Indication Outlook

• Bone and cartilage repair


• Cardiovascular disease


• Inflammatory & immunological diseases


• Liver diseases


• Cancer


• GvHD


• Others

Mesenchymal Stem Cells Application Outlook

• Disease modeling


• Drug development & discovery


• Stem cell banking


• Tissue engineering


• Toxicology studies


• Others

Mesenchymal Stem Cells Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America